255 related articles for article (PubMed ID: 20210778)
1. Feline immunodeficiency virus model for designing HIV/AIDS vaccines.
Yamamoto JK; Sanou MP; Abbott JR; Coleman JK
Curr HIV Res; 2010 Jan; 8(1):14-25. PubMed ID: 20210778
[TBL] [Abstract][Full Text] [Related]
2. Lessons Learned in Developing a Commercial FIV Vaccine: The Immunity Required for an Effective HIV-1 Vaccine.
Sahay B; Yamamoto JK
Viruses; 2018 May; 10(5):. PubMed ID: 29789450
[TBL] [Abstract][Full Text] [Related]
3. Dual-subtype FIV vaccine (Fel-O-Vax FIV) protection against a heterologous subtype B FIV isolate.
Pu R; Coleman J; Coisman J; Sato E; Tanabe T; Arai M; Yamamoto JK
J Feline Med Surg; 2005 Feb; 7(1):65-70. PubMed ID: 15686976
[TBL] [Abstract][Full Text] [Related]
4. Feline immunodeficiency virus (FIV) vaccine efficacy and FIV neutralizing antibodies.
Coleman JK; Pu R; Martin MM; Noon-Song EN; Zwijnenberg R; Yamamoto JK
Vaccine; 2014 Feb; 32(6):746-54. PubMed ID: 23800540
[TBL] [Abstract][Full Text] [Related]
5. Lack of protection against feline immunodeficiency virus infection among domestic cats in New Zealand vaccinated with the Fel-O-Vax® FIV vaccine.
Stickney A; Ghosh S; Cave NJ; Dunowska M
Vet Microbiol; 2020 Nov; 250():108865. PubMed ID: 33045631
[TBL] [Abstract][Full Text] [Related]
6. Dual-subtype vaccine (Fel-O-Vax FIV) protects cats against contact challenge with heterologous subtype B FIV infected cats.
Kusuhara H; Hohdatsu T; Okumura M; Sato K; Suzuki Y; Motokawa K; Gemma T; Watanabe R; Huang C; Arai S; Koyama H
Vet Microbiol; 2005 Jul; 108(3-4):155-65. PubMed ID: 15899558
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of a feline immunodeficiency virus vaccine.
Huang C; Conlee D; Loop J; Champ D; Gill M; Chu HJ
Anim Health Res Rev; 2004 Dec; 5(2):295-300. PubMed ID: 15984343
[TBL] [Abstract][Full Text] [Related]
8. Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats.
Tellier MC; Pu R; Pollock D; Vitsky A; Tartaglia J; Paoletti E; Yamamoto JK
AIDS; 1998 Jan; 12(1):11-8. PubMed ID: 9456250
[TBL] [Abstract][Full Text] [Related]
9. FIV vaccine development and its importance to veterinary and human medicine: a review FIV vaccine 2002 update and review.
Uhl EW; Heaton-Jones TG; Pu R; Yamamoto JK
Vet Immunol Immunopathol; 2002 Dec; 90(3-4):113-32. PubMed ID: 12459160
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 p24 vaccine protects cats against feline immunodeficiency virus infection.
Coleman JK; Pu R; Martin M; Sato E; Yamamoto JK
AIDS; 2005 Sep; 19(14):1457-66. PubMed ID: 16135898
[TBL] [Abstract][Full Text] [Related]
11. Utilization of feline ELISPOT for mapping vaccine epitopes.
Abbott JR; Pu R; Coleman JK; Yamamoto JK
Methods Mol Biol; 2012; 792():47-63. PubMed ID: 21956500
[TBL] [Abstract][Full Text] [Related]
12. Utilization of Feline ELISpot to Evaluate the Immunogenicity of a T Cell-Based FIV MAP Vaccine.
Sahay B; Aranyos AM; McAvoy A; Yamamoto JK
Methods Mol Biol; 2018; 1808():197-219. PubMed ID: 29956186
[TBL] [Abstract][Full Text] [Related]
13. Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates.
Pu R; Coleman J; Omori M; Arai M; Hohdatsu T; Huang C; Tanabe T; Yamamoto JK
AIDS; 2001 Jul; 15(10):1225-37. PubMed ID: 11426067
[TBL] [Abstract][Full Text] [Related]
14. Neutralising antibody response in domestic cats immunised with a commercial feline immunodeficiency virus (FIV) vaccine.
Bęczkowski PM; Harris M; Techakriengkrai N; Beatty JA; Willett BJ; Hosie MJ
Vaccine; 2015 Feb; 33(8):977-84. PubMed ID: 25613718
[TBL] [Abstract][Full Text] [Related]
15. The development of a vaccine against feline immunodeficiency virus.
Hosie MJ
Br Vet J; 1994; 150(1):25-39. PubMed ID: 8025833
[TBL] [Abstract][Full Text] [Related]
16. AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblasts.
Giannecchini S; Isola P; Sichi O; Matteucci D; Pistello M; Zaccaro L; Del Mauro D; Bendinelli M
J Virol; 2002 Jul; 76(14):6882-92. PubMed ID: 12072489
[TBL] [Abstract][Full Text] [Related]
17. Simian and feline immunodeficiency viruses: animal lentivirus models for evaluation of AIDS vaccines and antiviral agents.
Gardner MB
Antiviral Res; 1991 May; 15(4):267-86. PubMed ID: 1659310
[TBL] [Abstract][Full Text] [Related]
18. Sequence variation of the feline immunodeficiency virus genome and its clinical relevance.
Stickney AL; Dunowska M; Cave NJ
Vet Rec; 2013 Jun; 172(23):607-14. PubMed ID: 23749359
[TBL] [Abstract][Full Text] [Related]
19. Mechanism(s) of FIV vaccine protection.
Pu R; Tellier MC; Yamamoto JK
Leukemia; 1997 Apr; 11 Suppl 3():98-101. PubMed ID: 9209311
[TBL] [Abstract][Full Text] [Related]
20. Antibody Responses in Cats Following Primary and Annual Vaccination against Feline Immunodeficiency Virus (FIV) with an Inactivated Whole-Virus Vaccine (Fel-O-Vax
Westman M; Yang D; Green J; Norris J; Malik R; Parr YA; McDonald M; Hosie MJ; VandeWoude S; Miller C
Viruses; 2021 Mar; 13(3):. PubMed ID: 33809232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
